PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.
PharmAust's new CEO on his journey in biotech and vision for the company
PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss his appointment to the company and recent trial developments.
PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs, lowering the risks and costs of development.